Online citations, reference lists, and bibliographies.
← Back to Search

Surgery For Malignant Pleural Mesothelioma

D. Sugarbaker, A. Wolf
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding of this rare and aggressive malignancy. In the multimodality treatment paradigm, the goal of surgery is to provide a macroscopic complete resection (i.e., complete removal of all grossly visible tumor). Two operations have evolved: extrapleural pneumonectomy and pleurectomy/decortication. The former is indicated for patients with advanced locally invasive disease; the latter for patients with more superficial spread of tumor that spares the lung and fissures. If critical mediastinal structures (e.g., aorta and vertebral bodies) are found to be involved at thoracotomy, the tumor is classified as T4, and pleurectomy/decortication is recommended. Despite having more advanced disease, a subset of patients with favorable prognostic factors can experience extended survival by undergoing trimodality therapy with extrapleural pneumonectomy, chemotherapy and/or radiation. The influence of surgery goes beyond diagnosis and resection. Much of what we know about the biology of mesothelioma has been gleaned from studying the surgical pathophysiology, including the delineation of histopathologic subtypes, disease stage stratification with survival, the propensity for local (in contrast to systemic) recurrence, as well as the prognostic effect of epithelial versus nonepithelial cell type, extrapleural nodal involvement, tumor bulk and surgical margins. Pending the discovery of new drugs, the focus of clinical research over the next 5 years will emphasize refinements in patient selection, pathologic staging, molecular staging and other novel adjuvant therapies.
This paper references
10.1016/J.LUNGCAN.2007.09.018
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0960-7404(98)00019-X
Malignant pleural mesothelioma: a problematic review.
T. L. Moskal (1998)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1016/0360-3016(87)90173-8
Technique for external beam treatment for mesothelioma.
G. Kutcher (1987)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
10.1002/jso.21261
Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma
V. Ambrogi (2009)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1093/jnci/djp061
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
G. Gordon (2009)
10.1016/J.JTCVS.2009.11.072
Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
A. Mujoomdar (2010)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
Report of high-dose (175 mg/m 2 ) cisplatin-based heated intraoperative chemotherapy in patients undergoing extrapleural pneumonectomy
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1016/j.lungcan.2008.09.008
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
C. Lee (2009)
10.1053/j.semtcvs.2009.06.010
Current options for systemic therapy in mesothelioma.
D. Jackman (2009)
10.1016/J.EJCA.2007.08.028
Mesothelin targeted cancer immunotherapy.
R. Hassan (2008)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1200/JCO.2004.07.097
Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread.
J. Friedberg (2004)
10.1053/j.semtcvs.2009.07.001
Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.
J. Friedberg (2009)
10.1002/cncr.24886
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
10.1200/JCO.2005.04.6813
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
10.1016/J.ATHORACSUR.2007.06.066
Malignant pleural mesothelioma: surgical management in 285 patients.
P. Schipper (2008)
10.1016/j.jtcvs.2009.06.027
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Mor-Li Hartman (2010)
10.1016/j.jtcvs.2008.12.045
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
T. Yan (2009)
10.1001/archsurg.143.5.476
Implications and management of pancreatic fistulas following pancreaticoduodenectomy: the Massachusetts General Hospital experience.
G. Veillette (2008)
10.1053/j.semtcvs.2009.07.007
Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication.
A. Wolf (2009)
10.1016/S1010-7940(01)00594-2
Trimodality management of malignant pleural mesothelioma.
G. Maggi (2001)
10.1053/j.semtcvs.2009.06.007
Current status of screening for malignant pleural mesothelioma.
H. Pass (2009)
10.1378/CHEST.103.4_SUPPLEMENT.382S
Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.
V. Rusch (1993)
10.1016/j.athoracsur.2007.10.007
Outcomes after transhiatal and transthoracic esophagectomy for cancer.
A. Chang (2008)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1053/j.semtcvs.2009.07.003
Making the case for molecular staging of malignant pleural mesothelioma.
R. Bueno (2009)
Established histochemical staining protocol for mesothelioma that distinguished mesothelioma from lung adenocarcinoma
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1053/j.semtcvs.2009.06.008
Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication.
R. Flores (2009)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1016/j.ijrobp.2007.11.011
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
E. Miles (2008)
10.1053/j.semtcvs.2009.06.011
Current trends in radiologic management of malignant pleural mesothelioma.
R. Gill (2009)
10.1016/S0039-6060(99)70234-5
Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy.
J. Birkmeyer (1999)
10.1007/BF02303746
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
10.1038/sj.bjc.6604421
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
J. Sørensen (2008)
Reports the validation of the four-gene expression ratio test designed to predict resectability of patients undergoing extrapleural pneumonectomy
Reduced lung volume measured by CT predicts unresectability in mesothelioma patients. Presented at: 9th Biennial Conference of the International Mesothelioma Interest Group
A Mujoomdar
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.32388/9f0l2o
The American Joint Committee on Cancer.
O. Beahrs (1984)
10.1097/01.coc.0000144852.75613.56
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1016/j.jtcvs.2009.02.046
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
Extrapleural pulmonary resection and pleurectomy (pleuro-pneumonectomy) for tuberculosis and empyema.
Sarot Ia (1950)
10.1016/S1556-0864(15)31536-7
Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma.
D. Sugarbaker (2006)
10.1016/J.JAMCOLLSURG.2007.02.067
Morbidity and mortality after liver resection: results of the patient safety in surgery study.
S. Virani (2007)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.1016/S0169-5002(05)81557-0
Standard therapy for the treatment of malignant pleural mesothelioma.
N. Vogelzang (2005)
10.1016/j.jtcvs.2008.07.055
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
L. Zellos (2009)
10.1016/S1010-7940(96)01008-1
Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery.
O. Soysal (1997)
10.1007/s12199-007-0017-6
Pathology of mesothelioma
K. Inai (2008)
10.1053/j.semtcvs.2009.06.009
Radiation therapy options for malignant pleural mesothelioma.
E. Baldini (2009)
Pathology of diffuse malignant pleural mesothelioma.
J. Corson (1997)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1016/S0003-4975(02)04474-0
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
J. Friedberg (2003)
Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
J. Corson (1982)
Malignant mesothelioma of the pleura . A prospective therapeutic study of 132 patients from 1981 – 1985
A Calavrezis (1988)
Extrapleural pulmonary resection and pleurectomy (pleuro-pneumonectomy) for tuberculosis and empyema.
Irving Arthur Sarot (1950)
World Health Organization International Histological Classification of Tumours: Histological Typing of Lung and Pleural Tumours (3 rd Edition)
W D Travis (1999)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Reduced lung volume measured by CT predicts unresectability in mesothelioma patients
A Mujoomdar
• Review of the current status of systemic chemotherapy in mesothelioma
10.1002/JSO.1143
Survival after conservative (palliative) management of pleural malignant mesothelioma
N. Merritt (2001)
10.1007/BF01728801
Malignant mesothelioma of the pleura
A. Calavrezos (2005)



This paper is referenced by
10.1016/j.lungcan.2020.05.032
Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study.
Andrew B Thompson (2020)
Primary pleuropulmonary neoplasms in childhood: fourteen cases from a single center.
H. Demir (2011)
10.1016/B978-1-4377-1560-6.00058-5
Lung, Chest Wall, Pleura, and Mediastinum
J. Putnam (2012)
10.1007/978-1-4471-6404-3_50
Pleurectomy Versus Radical Pleuropneumonectomy for Malignant Pleural Mesothelioma
S. R. Carr (2014)
10.1016/j.athoracsur.2014.01.050
Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study.
L. Spaggiari (2014)
10.1007/s10353-010-0559-5
The clinical impact of photodynamic therapy in thoracic surgery
J. Lindenmann (2010)
Chirurgische Aspekte des malignen Pleuramesothelioms
Aus Sicht der Pathologie (2013)
10.1016/j.jtho.2018.08.001
Surgery in Malignant Pleural Mesothelioma
R. Bueno (2018)
10.1016/j.thorsurg.2016.04.003
Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.
A. Wolf (2016)
Investigating methods regarding diagnostic and prognostic biomarkers for malignant mesothelioma
H. Matsuzaki (2015)
10.1093/icvts/ivs542
What is the survival after surgery for localized malignant pleural mesothelioma?
Sandra Gelvez-Zapata (2013)
10.1016/j.bmc.2012.09.018
Carbonic anhydrase IX in malignant pleural mesotheliomas: a potential target for anti-cancer therapy.
Antti J Kivelä (2013)
10.1016/j.ygyno.2015.05.003
The impact of pleural disease on the management of advanced ovarian cancer.
C. Escayola (2015)
Cytotoxic activity of biosourced astins against malignant pleural mesothelioma cells
Gaëlle Redouté (2018)
10.3978/j.issn.2225-319X.2012.11.05
Standardizing surgical treatment in malignant pleural mesothelioma.
D. Rice (2012)
10.1007/s00044-012-9985-1
Scouting new molecular targets for CFTR therapy: the HSC70/BAG-1 complex. A computational study
E. Cichero (2012)
10.1016/j.aanat.2019.151415
When and why was the phrenicoabdominal branch of the left phrenic nerve placed into the esophageal hiatus in German textbooks of anatomy? An anatomical study on 400 specimens reevaluating its course through the diaphragm.
Bettina Pretterklieber (2019)
10.1016/j.soc.2020.06.002
Updates in Staging and Management of Malignant Pleural Mesothelioma.
A. Wolf (2020)
10.1016/j.athoracsur.2012.02.009
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.
J. Friedberg (2012)
Wczesne i odległe wyniki leczenia złośliwego międzybłoniaka opłucnej na podstawie analizy 170 przypadków
Bryl Maciej (2012)
10.1007/978-3-030-16884-1_14
Role of Radiotherapy in Malignant Pleural Mesothelioma
M. Scorsetti (2019)
10.1016/j.lungcan.2013.10.013
Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.
E. Minatel (2014)
Growth factor-induced epithelioid-sarcomatoid transition in malignant pleural mesothelioma cells?
Christina Wagner (2015)
10.1016/j.thorsurg.2014.07.014
Extrapleural pneumonectomy for pleural malignancies.
A. Wolf (2014)
10.1016/j.ejcts.2010.12.024
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
D. Sugarbaker (2011)
10.2995/JACSURG.25.687
胸膜中皮腫の外科治療を巡る諸問題 : EPPかP/Dか
坪田 紀明 (2011)
10.1245/s10434-019-07357-0
How Old is Too Old to Operate for Mesothelioma?
J. Karush (2019)
10.21037/atm.2016.03.17
Perspective on malignant pleural mesothelioma diagnosis and treatment.
Ori Wald (2016)
10.2217/LMT.15.16
Multimodality therapy for malignant pleural mesothelioma: surgery plus chemoradiotherapy?
A. Wolf (2015)
10.1053/j.ro.2013.03.017
Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations.
M. Truong (2013)
10.1245/s10434-019-07357-0
How Old is Too Old to Operate for Mesothelioma?
DO JustinM.Karush (2019)
10.1007/s00104-012-2431-6
Chirurgische Aspekte des malignen Pleuramesothelioms
A. Fisseler-Eckhoff (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar